The opinion supports 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks; a European Commission decision is expected in the coming months.

Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.

With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.

Faculty at an OncLive Scientific Interchange and Workshop discussed individualizing frontline immune checkpoint inhibitor selection in metastatic NSCLC.

The NCCN update adds locally advanced CSCC to the category 2A listing cosibelimab received in metastatic disease in 2025.

The 510(k) clearance covers an MRI-derived AI risk score for stage I to IIIA disease; the high-risk category carried an HR of 2.81 for recurrence.